Mindeudesivir
Based on 1 Customer Validation
GS-621763-d1 is the deuterium labeled GS-621763 (HY-145119). GS-621763, an orally bioavailable proagent of GS-441524, shows antiviral activity against SARS-CoV-2 pathogenesis in mice.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.20%
- CAS. Nr.: 2647442-33-7
- Formel: C24H30DN5O7
- Molecular Weight:502.54
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-102074
ERDRP-0519MeV Polymerase Inhibitor -
HY-137958
Bemnifosbuvir hemisulfateHCV/SARS-CoV-2 Inhibitor -
HY-145994
ObeldesivirAtiviral Agent -
HY-12983A
LumicitabineRSV Polymerase Inhibitor -
HY-136259
ML1883CLpro Inhibitor -
HY-100442
PaquinimodS100A8/A9 Inhibitor -
HY-138687
Nirmatrelvir3CLPRO Inhibitor -
HY-143216
EnsitrelvirSARS-CoV-2 3CL Protease Inhibitor -
HY-125033
EIDD-1931Anti-Virus Agent -
HY-143216A
Ensitrelvir fumarateSARS-CoV-2 3CL Protease Inhibitor -
HY-147020
CoronastatAnti-infection Agent -
HY-138687R
Nirmatrelvir (Standard)3CLPRO Inhibitor
Biologische Aktivität
Beschreibung
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MT4 | CC50 |
280 μM
Compound: X6
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability treated for 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability treated for 5 days by MTT assay
|
[PMID: 37229831] |
In Vitro
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Anwendung
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS. Nr. 2647442-33-7
-
Unlabeled CAS 2647442-13-3
-
Appearance Solid
-
Molecular Weight 502.54
-
Formel C24H30DN5O7
-
Color White to off-white
-
SMILES
N#C[C@](O[C@@H]1COC(C(C)C)=O)(C2=CC([2H])=C3N2N=CN=C3N)[C@@H]([C@@H]1OC(C(C)C)=O)OC(C(C)C)=O
-
Synonyms
VV116 free base; GS-621763-d1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 100 mg/mL (198.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (279 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
[2]. Schäfer A, et al. Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice. bioRxiv [Preprint]. 2021 Sep 17:2021.09.13.460111. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9899 mL | 9.9495 mL | 19.8989 mL | 49.7473 mL |
| 5 mM | 0.3980 mL | 1.9899 mL | 3.9798 mL | 9.9495 mL | |
| 10 mM | 0.1990 mL | 0.9949 mL | 1.9899 mL | 4.9747 mL | |
| 15 mM | 0.1327 mL | 0.6633 mL | 1.3266 mL | 3.3165 mL | |
| 20 mM | 0.0995 mL | 0.4975 mL | 0.9949 mL | 2.4874 mL | |
| 25 mM | 0.0796 mL | 0.3980 mL | 0.7960 mL | 1.9899 mL | |
| 30 mM | 0.0663 mL | 0.3316 mL | 0.6633 mL | 1.6582 mL | |
| 40 mM | 0.0497 mL | 0.2487 mL | 0.4975 mL | 1.2437 mL | |
| 50 mM | 0.0398 mL | 0.1990 mL | 0.3980 mL | 0.9949 mL | |
| 60 mM | 0.0332 mL | 0.1658 mL | 0.3316 mL | 0.8291 mL | |
| 80 mM | 0.0249 mL | 0.1244 mL | 0.2487 mL | 0.6218 mL | |
| 100 mM | 0.0199 mL | 0.0995 mL | 0.1990 mL | 0.4975 mL |
Mindeudesivir Related Classifications
HY-145119S Related Classifications
Powered by Bioz